Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

Published:2022-04-26 Issue:3 Volume:292 Page:477-491
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Brun Marthe Kirkesæther¹²^ORCID,Goll Guro Løvik¹^ORCID,Jørgensen Kristin Kaasen³,Sexton Joseph¹,Gehin Johanna Elin²⁴,Sandanger Øystein⁵,Olsen Inge Christoffer⁶,Klaasen Rolf Anton⁴,Warren David John⁴,Mørk Cato⁷,Kvien Tore K.¹²,Jahnsen Jørgen²³,Bolstad Nils⁴,Haavardsholm Espen A.¹²,Syversen Silje Watterdal¹

Affiliation:

1. Division of Rheumatology and Research Diakonhjemmet Hospital Oslo Norway

2. Institute of Clinical Medicine University of Oslo Oslo Norway

3. Department of Gastroenterology Akershus University Hospital Lørenskog Norway

4. Department of Medical Biochemistry Oslo University Hospital Oslo Norway

5. Section of Dermatology Oslo University Hospital Oslo Norway

6. Department of Research Support for Clinical Trials Oslo University Hospital Oslo Norway

7. Akershus Dermatology Center Lørenskog Norway

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13495

Reference44 articles.

1. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

2. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

4. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

5. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología (English Edition);2024-08

2. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17

3. Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report;Biomedicines;2024-04-03

4. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials;The Lancet Rheumatology;2024-04

5. Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies;Current Issues in Molecular Biology;2024-03-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3